Who founded Normunity?

Normunity was founded by Rachel Humphrey, Lieping Chen.

Who are Normunity's investors?

Normunity's investors include Sanofi Ventures, Taiho Ventures, LLC, Pfizer Ventures, Samsara BioCapital, Canaan Partners, Connecticut Innovations, OUP (Osage University Partners), Pfizer Venture Investments and 5 more.

Normunity

28 employees on LinkedIn · 14 known investors

Find your way into Normunity

Paths you didn't know you had: your email and LinkedIn already hold routes to the Normunity team. We find them for you
2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Normunity develops biologic anti-cancer therapies that act at the interface of the immune system and tumors, targeting mechanisms tumors use to evade immune surveillance. The company builds its drug discovery pipeline through a partnership with the Lieping Chen lab at Yale School of Medicine, focusing on solid tumors.

Biotech Healthtech

Founders & leadership

Rachel HumphreyFounding Chief Executive OfficerRachel Humphrey is Founding CEO of Normunity, which develops biologic anti-cancer therapies targeting tumor immune evasion mechanisms. She brings over 25 years of pharmaceutical industry experience, including executive roles at Bristol Myers Squibb and AstraZeneca, Chief Medical Officer positions at multiple biotechnology companies, and board service at both public and private firms.

Lieping ChenScientific Founder

Mitchell KeeganChief Development OfficerHe has more than 20 years of pharmaceutical industry experience spanning clinical development, preclinical pharmacology, regulatory affairs, manufacturing, and business development across antibodies, small molecules, recombinant proteins, and medical devices, with a track record of advancing drug candidates through regulatory approval.

William LaRochelleChief Scientific OfficerChief Scientific Officer of Normunity, William LaRochelle has extensive background in cancer drug research and development with a focus on precision medicine approaches.

Stacy M. PlumChief Technology Officer

Investors · 14

Sanofi Ventures✓ confirmed by NormunityCambridge · $5M

How we know: Sanofi Ventures's portfolio page · the company's own site · pulse2.com · the VCSheet dataset · Not right? Tell us

Taiho Ventures, LLC✓ confirmed by NormunityMenlo Park

How we know: the company's own site · pulse2.com · Not right? Tell us

Pfizer Ventures✓ confirmed by Normunity

How we know: the company's own site · funding news · pulse2.com · Not right? Tell us

Samsara BioCapital✓ confirmed by NormunityMenlo Park

How we know: the company's own site · pulse2.com · Not right? Tell us

Canaan Partnerslisted by Canaan PartnersStamford · $500K – $20M

How we know: Canaan Partners's portfolio page · a partner's Signal profile · pulse2.com · Not right? Tell us

Connecticut Innovationslisted by Connecticut InnovationsNew Haven · $500K – $2M

How we know: Connecticut Innovations's portfolio page · pulse2.com · Not right? Tell us

OUP (Osage University Partners)listed by OUP (Osage University Partners)Bala Cynwyd · $1M – $20M

How we know: OUP (Osage University Partners)'s portfolio page · Not right? Tell us

Pfizer Venture Investmentslisted by Pfizer Venture Investments$5M – $20M

How we know: Pfizer Venture Investments's portfolio page · the VCSheet dataset · Not right? Tell us

Avoro Capital AdvisorsreportedNew York

How we know: a partner's Signal profile · Not right? Tell us

HongShan Capital GroupreportedHong Kong · $100K – $50M

How we know: pulse2.com · Not right? Tell us

Osage Venture PartnersreportedBala Cynwyd · $500K – $3M

How we know: pulse2.com · Not right? Tell us

Regeneron VenturesreportedGreenwich

How we know: pulse2.com · Not right? Tell us

YK BioventuresreportedBurlingame

How we know: funding news · pulse2.com · Not right? Tell us

Also in the syndicate · 1

Enavate Scienceslead

Funding

SEC filings, press & company announcements

Undisclosed amountSeries BJan 2025
Enavate Sciences (lead), Samsara BioCapital (lead), Canaan Partners, Connecticut Innovations, HongShan Capital Group, Osage Venture Partners, Pfizer Ventures, Regeneron Ventures, Sanofi Ventures, Taiho Ventures, YK Bioventures
Source ↗
Undisclosed amountSeries AOct 2022
Source ↗

Source: company announcements and press reports — follow each round's link for the claim.

Related companies · 1

ImmunomeImmunome is a clinical-stage oncology company developing targeted cancer therapies, including antibody-drug conjugates (ADCs) and small molecules, to address unmet medical needs in cancers such as lymphoma and bladder cancer. It also acquires targeted oncology assets and advances them through manufacturing and clinical development.

Companies working in the same space as Normunity.

In the news

Normunity Raises $65M in Series A Financingfinsmes.com · Oct 2022

About Us - Normunitynormunity.com · Aug 2022

Frequently asked questions

What does Normunity do?: Normunity develops biologic anti-cancer therapies that act at the interface of the immune system and tumors, targeting mechanisms tumors use to evade immune surveillance. The company builds its drug discovery pipeline through a partnership with the Lieping Chen lab at Yale School of Medicine, focusing on solid tumors.
Who founded Normunity?: Normunity was founded by Rachel Humphrey, Lieping Chen.
Who are Normunity's investors?: Normunity's investors include Sanofi Ventures, Taiho Ventures, LLC, Pfizer Ventures, Samsara BioCapital, Canaan Partners, Connecticut Innovations, OUP (Osage University Partners), Pfizer Venture Investments and 5 more.